Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Director · CEO and President | March 10, 2022 | March 14, 2022 |
| FEMASYS INCFEMY · Entity 7510 | Director | June 14, 2023 | June 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date March 10, 2022 · Filed March 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2032-03-10 | Direct | 375,000 |
Reported balance
After 2022-03-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-10 · Grant · Acquired 375,000 · Balance 375,000 F1: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
FEMASYS INC
Report date June 14, 2023 · Filed June 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2033-06-14 | Direct | 17,000 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 17,000 · Balance 17,000 F1: The shares underlying the stock option will vest in annual one-third (1/3) increments over a three (3) year period beginning on June 14, 2024, assuming continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option will vest in annual one-third (1/3) increments over a three (3) year period beginning on June 14, 2024, assuming continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2019 Filed Apr 1, 2019 16:40 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 263 | $6.91 | $1,817.33 |
DisclosureSEC source: 0001214659-19-002418 · marketforms-44722.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,614 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| March 31, 2019 Filed Apr 1, 2019 16:40 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-002418 · marketforms-44722.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 17:24 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 14,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-001724 · marketforms-44306.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,860 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 17:24 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 4,725 | $8.05 | $38,036.25 |
DisclosureSEC source: 0001214659-19-001724 · marketforms-44306.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,548 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 17:24 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-001724 · marketforms-44306.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 16:46 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 325,000 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001214659-19-001750 · marketforms-44354.xml · derivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 17:23 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Unit · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-19-000279 · form4.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,978 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on September 30, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. F2 · derivative.expiration_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on September 30, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 17:23 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 162 | $6.30 | $1,020.60 |
DisclosureSEC source: 0001140361-19-000279 · form4.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,701 Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 17:23 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-19-000279 · form4.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 16:02 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Unit · Derivative | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-044533 · form4.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,432 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. F2 · derivative.expiration_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 16:02 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 7,177 | $8.59 | $61,650.43 |
DisclosureSEC source: 0001140361-18-044533 · form4.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,534 Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 16:02 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-044533 · form4.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 635,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 16:01 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 1,000 | $9.87 | $9,870.00 |
DisclosureSEC source: 0001140361-18-043897 · form4.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 621,139 Read SEC document |
| November 23, 2018 Filed Nov 26, 2018 13:38 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 1,950 | $9.90 | $19,305.00 |
DisclosureSEC source: 0001140361-18-043651 · form4.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,139 Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 13:38 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 6,000 | $10.17 | $61,020.00 |
DisclosureSEC source: 0001140361-18-043651 · form4.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,189 Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 16:38 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Unit · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-039945 · form4.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,307 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on September 30, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. F3 · derivative.expiration_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on September 30, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 16:38 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 162 | $17.51 | $2,836.62 |
DisclosureSEC source: 0001140361-18-039945 · form4.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,229 F2 · balance_after: Includes 396,040 shares of common stock currently issued and outstanding, which are held by Mr. Kendall in constructive trust for his former spouse pursuant to a divorce settlement agreement reached in November 2016 and which will be transferred and come under the control of Mr. Kendall's former spouse in the near future. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 16:38 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-039945 · form4.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 396,040 shares of common stock currently issued and outstanding, which are held by Mr. Kendall in constructive trust for his former spouse pursuant to a divorce settlement agreement reached in November 2016 and which will be transferred and come under the control of Mr. Kendall's former spouse in the near future. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 17:41 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Unit · Derivative | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-037870 · form4.xml · derivative · entry 3 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,004 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. F3 · derivative.expiration_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 17:41 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 6,510 | $18.01 | $117,245.10 |
DisclosureSEC source: 0001140361-18-037870 · form4.xml · nonDerivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,062 F2 · balance_after: Includes 396,040 shares of common stock currently issued and outstanding, which are held by Mr. Kendall in constructive trust for his former spouse pursuant to a divorce settlement agreement reached in November 2016 and which will be transferred and come under the control of Mr. Kendall's former spouse in the near future. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 17:41 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-037870 · form4.xml · nonDerivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,014,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 396,040 shares of common stock currently issued and outstanding, which are held by Mr. Kendall in constructive trust for his former spouse pursuant to a divorce settlement agreement reached in November 2016 and which will be transferred and come under the control of Mr. Kendall's former spouse in the near future. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 18:40 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantRestricted Stock Unit · Derivative | 2,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-036637 · form4.xml · derivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,636 Underlying: Common Stock · 2,636 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on September 30, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. F3 · derivative.expiration_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on September 30, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 18:40 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 28,043 | $0.00 Strike: $16.46 | $0.00 |
DisclosureSEC source: 0001140361-18-036637 · form4.xml · derivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,043 Underlying: Common Stock · 28,043 shares Expires 2028-08-15 F1 · derivative.exercise_date: The shares underlying the options vest in 36 equal (or as nearly equal as possible) monthly installments beginning on September 30, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:13 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantRestricted Stock Unit · Derivative | 116,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-033744 · form4.xml · derivative · entry 2 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,576 Underlying: Common Stock · 116,576 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. F3 · derivative.expiration_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:13 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 240,165 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-18-033744 · form4.xml · derivative · entry 1 Kendall Keith J · CIK 0001406834 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,165 Underlying: Common Stock · 240,165 shares Expires 2028-07-24 F1 · derivative.exercise_date: The shares underlying the options vest in 36 equal (or as nearly equal as possible) monthly installments beginning on August 31, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.